阿尔茨海默病医疗之旅的未来验证

Emerging Best PracticesAcross Europe Executive Summary With the arrival of disease-modifying therapies (DMTs), blood-based biomarkers(BBMs) and digital solutions, health systems across Europe face a pivotalopportunity to transform Alzheimer’s disease (AD) diagnosis and care.These innovations bring new hope but also highlight the urgent need forinvestment in healthcare systems to ensure that scientific progress translatesinto population-level benefit. Timely diagnosis, coordinated care, and equitableaccess are no longer aspirational goals; they are prerequisites for ensuringthat patients and their supporters can benefit from emerging treatments.Yet, persistent gaps in the patient pathway, ranging from public awareness todiagnostic capacity and long-term care, threaten to undermine this progress. What We Found? This report captures a growing movement across Europe:one where local initiatives, often spearheaded by dedicatedprofessionals and institutions, are pioneering scalable,person-centred solutions to address long-standing gaps in ADdiagnosis and care. These efforts are not theoretical; they arehappening now. We identify digital tools that are making earlydiagnosis more accessible, multidisciplinary care models thatare improving quality of life, and data registries that are guidingmore strategic policy and resource allocation. What sets thisreport apart is its emphasis on proven successes. It highlightsreal-world examples that demonstrate how, even in the faceof health system constraints, meaningful progress is possible. Why This Report? Why Now? To our knowledge, this report represents the first detailed attempt to identify,document, and disseminate effective, scalable solutions in AD awareness,diagnosis, and care across Europe. It aims to show how, independently ofbroader health system challenges, targeted interventions can address criticalgaps in the experiences of people living with AD and those who support them.By bringing forward real-world examples from multiple countries, the reportoffers a practical blueprint that others can adapt or replicate, whether to inspirelocal innovation or inform national strategies. This is critically needed given the scale and urgency of the AD challenge.Millions are currently living with AD, and the numbers are projected to nearlydouble by 2050. European governments have increasingly acknowledgedthe need for coordinated action, with many adopting national strategiesfocusing on early diagnosis, integrated care, public education and support forthose providing care. However, implementation remains uneven, as stigma,underutilisation of primary care and inadequate public awareness continueto hinder timely detection. These challenges are compounded by persistentdisparities in access, workforce shortages, and funding constraints. This report responds to that reality. It draws on insights from diversestakeholders and highlights practical opportunities for progress. It is intendedto inform policymakers, who are being called to invest in their countries’readiness, on where efforts should be placed to ensure that the journey ofpeople living with AD and those who support them is as smooth, timely, andequitable as possible. Through examples from multiple European countries, itpresents best practices that strengthen timely and accurate diagnosis, expandaccess to high-quality, sustainable care, and demonstrate what is both provenand achievable in practice for addressing this growing crisis. The Challenges and the Opportunities A Paradigm Shift: New Toolsand Thinking The Time to Act Is Now The Growing Burden of Alzheimer’sDisease (AD) in Europe The urgency of the Alzheimer’s diseasechallenge is undeniable, but so too isour inherent capacity for meaningfulchange. With strategic, sustainedinvestment in proven solutions anda commitment to scaling up bestpractices, we can and must build moreefficient healthcare systems that areequipped to effectively manage andmitigate the devastating impact thatAlzheimer’s disease has on familiesand their loved ones. Despite the success of these promising initiatives,broader systemic challenges remain, includinguneven access, limited healthcare workforcecapacity, underfunded infrastructure and a lackof cohesive national strategies. Therefore, the timeto act is now—before demographic pressures andsystem fragmentation further widen these gaps. Over the past decade, approaches to AD careand diagnosis have experienced a profoundtransformation. The traditional model—focusedon late-stage symptom management—is givingway to a more proactive, person-centred anddata-driven paradigm. Increasing emphasis is beingplaced on early and accurate diagnosis, enabledby tools such as cognitive testing and blood-based biomarkers (BBMs), which offer scalableand less invasive alternatives to positron emissiontomography (PET) imaging and cerebrospinal fluid(CSF) testing, alongside preventive interventionstargeting modifiable risk factors and longitudinalmonitoring